```
L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```




```
G1 H,Ak
G2 N,Hy


Structure attributes must be viewed using STN Express query preparation.


=> s l1
SAMPLE SEARCH INITIATED 08:00:23 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    24397 TO ITERATE

  8.2% PROCESSED     2000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       478592 TO   497288
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 08:00:45 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   490706 TO ITERATE

100.0% PROCESSED   490706 ITERATIONS                            140 ANSWERS
SEARCH TIME: 00.00.06

L3          140 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               178.82     179.03

FILE 'CAPLUS' ENTERED AT 08:00:55 ON 16 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
```

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 16 Jun 2008 VOL 148 ISS 25
FILE LAST UPDATED: 15 Jun 2008 (20080615/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l3
L4 7 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:146795 CAPLUS
DOCUMENT NUMBER: 146:229197
TITLE: 6-Membered aryl and heteroaryl derivatives for treating viruses and their preparation and pharmaceutical compositions
INVENTOR(S): Botyanszki, Janos; Shi, Dong-Fang; Roberts, Christopher Don; Schmitz, Franz Ulrich
PATENT ASSIGNEE(S): Genelabs Technologies, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 45pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070032488	A1	20070208	US 2006-499461	20060803
WO 2007019397	A2	20070215	WO 2006-US30631	20060803
WO 2007019397	A3	20070816		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2005-705886P P 20050805

OTHER SOURCE(S): MARPAT 146:229197
GI

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)





AB Disclosed are compds. of formulas I, II, and III, compns. and methods for treating Flaviviridae family virus infections. Compds. of formulas I, II, and III wherein B and D are independently N and CR1L1; A and E are independently N and CR2; R is (un)substituted alkyl, (un)substituted cycloalkyl, (un)substituted cycloalkenyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted heterocyclic, and (un)substituted (hetero)aryl; R1 is H, (un)substituted alkyl, (un)substituted cycloalkyl, (un)substituted cycloalkenyl, (un)substituted (hetero)aryl, CO2H and derivs., etc.; R2 is H, halo, (un)substituted C1-2 alkyl, (un)substituted C2-3 alkenyl, and (un)substituted cyclopropyl; L and L1 is a bond, (un)substituted C1-3 alkylene, (un)substituted C2-3 alkenylene, (un)substituted C2-3 alkynylene, (un)substituted (hetero)arylene, etc.; Z is H, halo, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynylene, (un)substituted (hetero)aryl, CO2H and derivs., etc.; Ar is (un)substituted (hetero)aryl; and their pharmaceutically acceptable salts, esters, stereoisomers, prodrugs, and tautomers thereof are claimed. Example compound IV was prepared by amidation of 3-(2-carboxyvinyl)-5-cyclohexyl-4-(furan-3-yl)benzoic acid Me ester with morpholine; the resulting 3-cyclohexyl-4-(furan-3-yl)-5-(3-oxo-3-(morpholin-4-yl)propenyl)benzoic acid Me ester underwent hydrolysis to give compound IV. All the invention compds. were evaluated for their antiviral activity.
IT 924283-01-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(Uses)
(drug candidate; prepn. of aryl and heteroaryl derivs. useful in treatment and prevention of viral infections)
RN 924283-01-2 CAPLUS
CN Cyclopentanecarboxylic acid, 1-[[3-cyclohexyl-4-[2-(2,4-dimethyl-5-thiazolyl)-6-quinolinyl]-5-[2-(4-morpholinyl)-2-oxoethyl]benzoyl]amino]- (CA INDEX NAME)



IT 924283-29-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of aryl and heteroaryl derivs. useful in treatment and prevention of viral infections)
RN 924283-29-4 CAPLUS
CN Benzamide, 3-cyclohexyl-4-[2-(2,4-dimethyl-5-thiazolyl)-6-quinolinyl]-5-[2-(4-morpholinyl)-2-oxoethyl]- (CA INDEX NAME)



L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:1127322 CAPLUS
DOCUMENT NUMBER: 142:74358
TITLE: Preparation of benzamide derivatives as capsaicin receptor VR1 activation inhibitors
INVENTOR(S): Kuramochi, Takahiro; Asai, Norio; Ikegai, Kazuhiro; Akamatsu, Seijiro; Harada, Hironori; Ishikawa, Noriko; Shirakami, Shohei; Miyamoto, Satoshi; Watanabe, Toshihiro; Kiso, Tetsuo
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 100 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004110986	A1	20041223	WO 2004-JP8479	20040610

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004247559	A1	20041223	AU 2004-247559	20040610
CA 2526387	A1	20041223	CA 2004-2526387	20040610
EP 1632477	A1	20060308	EP 2004-736576	20040610

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

CN 1805923	A	20060719	CN 2004-80016215	20040610
BR 2004011083	A	20060725	BR 2004-11083	20040610
IN 2005DN05582	A	20080208	IN 2005-DN5582	20051201
MX 2005PA13434	A	20060317	MX 2005-PA13434	20051209
US 20070167444	A1	20070719	US 2005-560282	20051212
NO 2006000167	A	20060310	NO 2006-167	20060111

PRIORITY APPLN. INFO.: JP 2003-167865 A 20030612
JP 2003-405086 A 20031203
WO 2004-JP8479 W 20040610

OTHER SOURCE(S): MARPAT 142:74358
GI

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB Tittle compds. I [A = NR11R12, etc.; R11, R12 = H, halo, etc.; L = alkylene; ring D, E = mono- or dicyclic hydrocarbon ring, etc.; R1-R9 = H, halo, etc.; R10 = H, alkyl] were prepared For example, HBTU-mediated acylation of 3-methoxyaniline with 2-(piperidin-1-ylmethyl)biphenyl-4-carboxylic acid followed by treatment with HCl afforded compound II. In VR1 receptor binding assays, compound II exhibited the IC50 value of ≤1 μM. Compds. I are claimed useful as VR1 activation inhibitors for the treatment of pains.

IT 813420-54-1P 813420-56-3P 813420-92-7P
813421-14-6P 813421-18-0P 813421-36-2P
813421-47-5P 813421-49-7P 813421-50-0P
813421-51-1P 813421-52-2P 813421-78-2P
813421-79-3P 813421-80-6P 813421-81-7P
813421-82-8P 813421-84-0P 813421-89-5P
813421-90-8P 813421-91-9P 813421-93-1P
813421-95-3P 813421-97-5P 813421-99-7P
813422-01-4P 813422-05-8P 813422-08-1P
813422-09-2P 813422-12-7P 813422-14-9P
813422-18-3P 813422-19-4P 813422-20-7P
813422-21-8P 813422-22-9P 813422-23-0P
813422-25-2P 813422-26-3P 813422-27-4P
813422-28-5P 813422-29-6P 813422-30-9P
813422-34-3P 813422-35-4P 813422-36-5P

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
813422-37-6P 813422-38-7P 813422-39-8P
813422-40-1P 813422-41-2P 813422-42-3P
813422-45-6P 813422-46-7P 813422-47-8P
813422-48-9P 813422-51-4P 813422-52-5P
813422-58-1P 813422-61-6P 813422-66-1P
813422-67-2P 813423-16-4P, N-(1-Methyl-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide
813423-18-6P, N-(1-Methyl-2-oxo-1,2-dihydroquinolin-7-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide 813423-20-0P, N-(3-Methyl-2-oxo-1,2-dihydroquinolin-7-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide 813423-22-2P,

2-[[Ethyl(tetrahydro-2H-pyran-4-yl)amino]methyl]-N-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)biphenyl-4-carboxamide 813423-23-3P, N-(1-Methyl-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)-3-(piperidin-1-ylmethyl)-4-(2-thienyl)benzamide 813423-24-4P, 2-[[Ethyl(tetrahydro-2H-thiopyran-4-yl)amino]methyl]-N-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)biphenyl-4-carboxamide 813423-26-6P, N,N-Diethyl-4-[(4-[[(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)amino]carbonyl]biphenyl-2-yl)methyl]morpholine-3-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzamide derivs. as capsaicin receptor VR1 activation inhibitors for treatment of pains)

RN 813420-54-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-(1-piperidinylmethyl)-N-(1,2,3,4-tetrahydro-1-methyl-7-quinolinyl)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 813420-53-0
CMF C29 H33 N3 O



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 813420-56-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-(1-piperidinylmethyl)-N-3-quinolinyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 813420-92-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-(1-piperidinylmethyl)-N-7-quinolinyl-, hydrobromide (1:2) (CA INDEX NAME)



● 2 HBr

RN 813421-14-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(4-hydroxy-2-quinolinyl)-2-(1-piperidinylmethyl)- (CA INDEX NAME)



RN 813421-18-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-(1-piperidinylmethyl)-N-(1,2,3,4-tetrahydro-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 813421-36-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-(1-piperidinylmethyl)-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 813421-47-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-(1-piperidinylmethyl)-N-(1,2,3,4-tetrahydro-3,3-dimethyl-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 813421-49-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-[(4-fluoro-1-piperidinyl)methyl]-N-(1,2,3,4-tetrahydro-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 813421-50-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-[(4-fluoro-1-piperidinyl)methyl]-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 813421-51-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-[(3,3-difluoro-1-piperidinyl)methyl]-N-(1,2,3,4-tetrahydro-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 813421-52-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-[(3,3-difluoro-1-piperidinyl)methyl]-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 813421-80-6 CAPLUS
CN 3-Piperidinecarboxamide, N,N-diethyl-1-[[4-[[(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 813421-81-7 CAPLUS
CN 2-Pyrrolidinecarboxamide, N,N-diethyl-1-[[4-[[(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 813421-82-8 CAPLUS

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 813421-78-2 CAPLUS
CN 2-Morpholinecarboxamide, N,N-diethyl-4-[[4-[[(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 813421-79-3 CAPLUS
CN 3-Morpholinecarboxamide, N,N-diethyl-4-[[4-[[(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

CN [1,1'-Biphenyl]-4-carboxamide, N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-2-[[3-(trifluoromethyl)-1-piperidinyl]methyl]-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 813421-84-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-[[3-[(1-oxobutyl)amino]-1-piperidinyl]methyl]-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 813421-83-9
CMF C33 H38 N4 O3



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 813421-89-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(1-ethyl-1,2,3,4-tetrahydro-2-oxo-7-quinolinyl)-2-(1-piperidinylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 813421-90-8 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1-(2-fluoroethyl)-1,2,3,4-tetrahydro-2-oxo-7-quinolinyl]-2-(1-piperidinylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 813421-91-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(1,2-dihydro-2-oxo-7-quinolinyl)-2-(1-piperidinylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 813421-93-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(1,2-dihydro-1,3-dimethyl-2-oxo-7-quinolinyl)-2-(1-piperidinylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 813421-95-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-(1-piperidinylmethyl)-N-(1,2,3,4-tetrahydro-3-methyl-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 813421-97-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(1,2-dihydro-1-methyl-2-oxo-7-quinolinyl)-2-(1-piperidinylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 813421-99-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(1,2-dihydro-3-methyl-2-oxo-7-quinolinyl)-

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
2-(1-piperidinylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 813422-01-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(6-chloro-1,2,3,4-tetrahydro-2-oxo-7-quinolinyl)-2-(1-piperidinylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 813422-05-8 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-(1-piperidinylmethyl)-N-(1,2,3,4-tetrahydro-2-oxo-1-propyl-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 813422-08-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-(1-piperidinylmethyl)-N-(1,2,3,4-tetrahydro-1,3-dimethyl-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 813422-09-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-[2-(1-piperidinyl)ethyl]-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 813422-12-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-chloro-6-(1-piperidinylmethyl)-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 813422-14-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-[(3,3-dimethyl-1-pyrrolidinyl)methyl]-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-, ethanedioate (1:1) (CA INDEX NAME)

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CM 1

CRN 813422-13-8
CMF C30 H33 N3 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 813422-18-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-(4-morpholinylmethyl)-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 813422-19-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-[[bis(2-methoxyethyl)amino]methyl]-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 813422-20-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-[[ethyl(2-methoxyethyl)amino]methyl]-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 813422-21-8 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-[[(3R)-3-methyl-1-pyrrolidinyl]methyl]-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 813422-22-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-[(3-methoxy-1-piperidinyl)methyl]-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 813422-23-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-[[(3R)-3-methyl-1-pyrrolidinyl]methyl]-N-(1,2,3,4-tetrahydro-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 813422-25-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-[(2,5-dimethyl-1-pyrrolidinyl)methyl]-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-, hydrochloride (1:1)

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(CA INDEX NAME)



● HCl

RN 813422-26-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-[(3-ethoxy-1-pyrrolidinyl)methyl]-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 813422-27-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-[(2,6-dimethyl-4-morpholinyl)methyl]-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 813422-28-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-fluoro-2-(1-piperidinylmethyl)-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 813422-29-6 CAPLUS
CN 2-Piperidinecarboxamide, N,N-diethyl-1-[[4-[[(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 813422-30-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-[(2-methyl-1-pyrrolidinyl)methyl]-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 813422-34-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-[[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]methyl]-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 813422-33-2
CMF C30 H33 N3 O3

Absolute stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 813422-35-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-fluoro-2-(1-piperidinylmethyl)-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 813422-36-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-2-(1-piperidinylmethyl)-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 813422-37-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-(1-piperidinylmethyl)-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-3'-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 813422-38-7 CAPLUS
CN Benzamide, 3-(1-piperidinylmethyl)-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-4-(2-thienyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 813422-39-8 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-chloro-2-(1-piperidinylmethyl)-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 813422-40-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-[[3-(1-piperidinylcarbonyl)-1-piperidinyl]methyl]-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 813422-41-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-(4-morpholinylmethyl)-N-(1,2,3,4-tetrahydro-3-methyl-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 813422-42-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-[(4-cyano-1-piperidinyl)methyl]-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 813422-45-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-[[[2-(diethylamino)-2-oxoethyl]ethylamino]methyl]-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 813422-46-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-[[ethyl(tetrahydro-2H-pyran-4-yl)amino]methyl]-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 813422-47-8 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-[[3-(methoxymethyl)-1-piperidinyl]methyl]-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 813422-48-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-[[2-(1-piperidinylmethyl)-1-pyrrolidinyl]methyl]-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-, hydrochloride (1:2) (CA INDEX NAME)

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



●2 HCl

RN 813422-51-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(1,2-dihydro-3-methyl-2-oxo-7-quinolinyl)-2-[[ethyl(2-methoxyethyl)amino]methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 813422-52-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(1,2-dihydro-3-methyl-2-oxo-7-quinolinyl)-2-[[3-(1-piperidinylcarbonyl)-1-piperidinyl]methyl]-, hydrochloride (1:1)
(CA INDEX NAME)

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 813422-58-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-[[ethyl(tetrahydro-2H-thiopyran-4-yl)amino]methyl]-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 813422-61-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-([1,3'-bipiperidin]-1'-ylmethyl)-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-, ethanedioate (1:1) (CA
INDEX NAME)

CM 1

CRN 813422-60-5
CMF C34 H40 N4 O2



L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 813423-18-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(1,2-dihydro-1-methyl-2-oxo-7-quinolinyl)-2-(1-piperidinylmethyl)- (CA INDEX NAME)



RN 813423-20-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(1,2-dihydro-3-methyl-2-oxo-7-quinolinyl)-2-(1-piperidinylmethyl)- (CA INDEX NAME)



RN 813423-22-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-[[ethyl(tetrahydro-2H-pyran-4-yl)amino]methyl]-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)- (CA INDEX NAME)



RN 813423-23-3 CAPLUS
CN Benzamide, 3-(1-piperidinylmethyl)-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-4-(2-thienyl)- (CA INDEX NAME)

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 813422-66-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-[[cyclohexyl(1-methylethyl)amino]methyl]-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 813422-67-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-[[bis(2-methylpropyl)amino]methyl]-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 813423-16-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-(1-piperidinylmethyl)-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)- (CA INDEX NAME)

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 813423-24-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2-[[ethyl(tetrahydro-2H-thiopyran-4-yl)amino]methyl]-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)- (CA INDEX NAME)



RN 813423-26-6 CAPLUS
CN 3-Morpholinecarboxamide, N,N-diethyl-4-[[4-[[(1,2,3,4-tetrahydro-1-methyl-2-oxo-7-quinolinyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]- (CA INDEX
NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:780670 CAPLUS
DOCUMENT NUMBER: 141:295874
TITLE: Preparation of tetrahydroquinoline derivatives as inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system.
INVENTOR(S): Quan, Mimi L.; Wang, Cailan; Zhou, Jinglan; Hangeland, Jon J.; Seiffert, Dietmar A.; Knabb, Robert M.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 150 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004080971	A1	20040923	WO 2004-US7216	20040310
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040235847	A1	20041125	US 2004-796396	20040309
US 7138412	B2	20061121		
EP 1601656	A1	20051207	EP 2004-719245	20040310
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
JP 2006519844	T	20060831	JP 2006-507012	20040310
US 20060223854	A1	20061005	US 2006-430588	20060509

PRIORITY APPLN. INFO.: US 2003-453812P P 20030311
US 2004-796396 A 20040309
WO 2004-US7216 W 20040310

OTHER SOURCE(S): MARPAT 141:295874
GI

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I

AB Title compds. [I; L1 = bond, CH2, CH2CH2, CH2O, CH2CO, etc.; L2 = bond, O, CO, CO2, S, SO, SO2, CONR8, SO2NR8, etc.; A = (substituted) carbocyclylene, heterocyclylene; B = (substituted) alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl; X1-X4 = CR1, CR2, N, etc.; R1 = H, F, Cl, Br, iodo, OCF3, CF3, cyano, NH2, alkylamino, dialkylamino, CONH2, CH2CH2NH2, etc.; R2 = H, F, Cl, Br, iodo, OCF3, CF3, cyano, NO2, amino, aminocarbonyl, (substituted) alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, etc.; R4 = H, F, haloalkyl, (substituted) alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, etc.; R5 = H, F, haloalkyl, (substituted) alkyl, alkenyl, alkynyl, heterocyclyl(alkyl), etc.; R13 = H, F, alkyl, aminoalkyl, CF3, aminocarbonyl, etc.; R14 = H, alkyl, aminoalkyl, F, CF3, aminocarbonyl, etc.; R13R14 = O; R15 = H, alkyl; R16 = H, alkyl, PhCH2, alkylcarbonyl, alkylsulfonyl, alkoxycarbonyl], were prepared Thus, 4-amidinobenzamidine monohydrochloride, styrene, 1'-formyl-1-benzyloxycarbonyl-4-isobutylcarbamoylbiphenyl (preparation given) and indium triflate were heated together at 70° in MeCN for 12 h to give a product which was hydrogenolyzed in MeOH/HOAc over Pd/C to give 2'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydroquinolin-2-yl)-4-isobutylcarbamoylbiphenyl-2-carboxylic acid. I inhibited Factor XIa with Ki ≤15 μM.
IT 762253-42-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of carbaminidoyltetrahydroquinoline derivs. as inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system)
RN 762253-42-9 CAPLUS
CN [1,1'-Biphenyl]-2,4-dicarboxamide, 3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-phenyl-2-quinolinyl]- (CA INDEX NAME)

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:792340 CAPLUS
DOCUMENT NUMBER: 135:331672
TITLE: Preparation of methionine derivatives as inhibitors of protein isoprenyl transferases
INVENTOR(S): Sebti, Said M.; Hamilton, Andrew D.; Augeri, David J.; Barr, Kenneth J.; Fakhoury, Stephen A.; Janowick, David A.; Kalvin, Douglas M.; O'connor, Stephen J.; Rosenberg, Saul H.; Shen, Wang; Swenson, Rolf E.; Sorenson, Bryan K.; Sullivan, Gerard M.; Tasker, Andrew S.; Wasicak, James T.; Nelson, Lissa T. J.; Henry, Kenneth J.; Wang, Le
PATENT ASSIGNEE(S): University of Pittsburgh, USA
SOURCE: U.S., 514 pp., Cont.-in-part of U.S. Ser. No. 852,858, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6310095	B1	20011030	US 1998-73794	19980507
ZA 9906763	A	20000515	ZA 1999-6763	19991027

PRIORITY APPLN. INFO.: US 1995-7247P P 19951106
US 1996-740909 B2 19961105
US 1997-852858 B2 19970507
US 1998-73794 A 19980507
US 1998-197279 A 19981120

OTHER SOURCE(S): MARPAT 135:331672
AB Compds. R3-Z-L1-aryl [aryl is a benzene ring having certain substituents R1, R2, R4; L1 is L4NR5L5 where L4 and L5 are absent or alkylene, R5 is H, alkanoyl, alkoxy, alkoxyalkyl, haloalkyl, etc.; Z is a covalent bond; R3 = cycloalkyl, alkoxy, alkyl, halogen, oxo, etc.] or their pharmaceutically acceptable salts, were prepared as inhibitors of protein isoprenyl transferases. Thus, N-[4-[(R)-thiazolidin-4-ylcarbonylamino]-2-phenylbenzoyl]methionine Me ester hydrochloride, prepared via amidation reaction, showed 92% inhibition of farnesyl transferase at 1x10-6 M.
IT 216231-94-6P 216234-40-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of methionine derivs. as inhibitors of protein isoprenyl transferases)
RN 216231-94-6 CAPLUS
CN L-Methionine, N-[[5-[(6-quinolinylamino)methyl][1,1'-biphenyl]-2-yl]carbonyl]- (CA INDEX NAME)

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.



RN 216234-40-1 CAPLUS
CN L-Methionine, N-[[5-[(butyl-2-quinolinylamino)methyl]-2'-methyl[1,1'-biphenyl]-2-yl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 216238-29-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of methionine derivs. as inhibitors of protein isoprenyl transferases)
RN 216238-29-8 CAPLUS
CN L-Methionine, N-[[5-[(butyl-2-quinolinylamino)methyl]-2'-methyl[1,1'-biphenyl]-2-yl]carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:34858 CAPLUS
DOCUMENT NUMBER: 132:93221
TITLE: Preparation of naphthalimidobenzamide derivatives as antitumor agents
INVENTOR(S): Noguchi, Kazuharu; Wakida, Motoji; Suzuki, Kenji; Yamada, Yuji; Asao, Tetsuji
PATENT ASSIGNEE(S): Taiho Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000001672	A1	20000113	WO 1999-JP3574	19990702
W: AU, CA, JP, KR, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2300069	A1	20000113	CA 1999-2300069	19990702
CA 2300069	C	20060117		
AU 9943963	A	20000124	AU 1999-43963	19990702
AU 727591	B2	20001214		
EP 1020446	A1	20000719	EP 1999-926895	19990702
EP 1020446	B1	20060315		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
JP 3357662	B2	20021216	JP 2000-558077	19990702
AT 320417	T	20060415	AT 1999-926895	19990702
US 6300331	B1	20011009	US 2000-508044	20000303
PRIORITY APPLN. INFO.:			JP 1998-189078 A	19980703
			WO 1999-JP3574 W	19990702

OTHER SOURCE(S): MARPAT 132:93221
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB 2-(3-Carbamoylphenyl)-1H-benz[de]isoquinoline-1,3(2H)-dione derivs. represented by general formula (I) or salts thereof (wherein R1 is hydrogen,NO2, OH, NH2, halo, cyano, CO2H, CONH2, ureido, alkyl, trihaloalkyl, alkoxy, etc.; Y is hydrogen or -CON(R4)-A2-X2; R2 and R4 are each independently hydrogen or alkyl; A1 and A2 are each independently linear or branched alkylene which may be interrupted by N(R3), O, S, CONH, NHCO, S(O), or SO2 (wherein R3 is hydrogen or the like); X1 is optionally substituted aryl, heteroaryl, aryldicarbonylimino, heteroaryldicarbonylimino, arylamino, heteroarylamino, arylcarbonylamino, etc.; and X2 is H, optionally substituted aryl, heterocyclyl, aryldicarbonylimino, heteroaryldicarbonylimino, arylamino, heteroarylamino, arylcarbamoyl, etc.; m = 1-3), which exhibit high affinity for DNA, are prepared Thus, a suspension of 711 mg

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

1-[N-[2-[(2-aminoethyl)amino]ethyl]carbamoyl]-3-(3-nitro-1,8-naphthalimido)-5-[N-(2-piperidinoethyl)carbamoyl]benzene hydrochloride, 0.5 mL Et3N, and 243 mg 3-nitro-1,8-naphthalic anhydride in 4 mL DMF was stirred at 60° for 30 min to give 72.2% title compd. (II.HCl). II.HCl in vivo inhibited the proliferation of human melanoma LOX, human pancreatic cancer PAN, human breast cancer MX1, and human stomach cancer AZ521 cells transplanted s.c. in nude mice by 96.2, 59.8, 71.8, and 79.5%, resp.

IT 254451-86-0P 254451-87-1P 254451-91-7P
254451-92-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of naphthalimidobenzamide derivs. as antitumor agents)
RN 254451-86-0 CAPLUS
CN 1,3-Benzenedicarboxamide, 5-(5-nitro-1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl)-N-[2-[[2-(5-nitro-1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl)ethyl]amino]ethyl]-N'-[2-[[2-[(3-quinolinylcarbonyl)amino]ethyl]amino]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



●3 HCl

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-B



RN 254451-87-1 CAPLUS
CN 1,3-Benzenedicarboxamide, 5-(5-nitro-1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl)-N-[2-[[2-(5-nitro-1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl)ethyl]amino]ethyl]-N'-[2-[[2-[(4-quinolinylcarbonyl)amino]ethyl]amino]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



●3 HCl

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
tetrahydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



●4 HCl

PAGE 1-B



REFERENCE COUNT: 20 THIS FORMAT THERE ARE 20 CITED REFERENCES AVAILABLE FOR RECORD. ALL CITATIONS AVAILABLE IN THE RE

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-B



RN 254451-91-7 CAPLUS
CN 1,3-Benzenedicarboxamide, 5-(5-nitro-1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl)-N,N'-bis[2-[[2-[(3-quinolinylcarbonyl)amino]ethyl]amino]ethyl]-, tetrahydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



●4 HCl

PAGE 1-B



RN 254451-92-8 CAPLUS
CN 1,3-Benzenedicarboxamide, 5-(5-nitro-1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl)-N,N'-bis[2-[[2-[(4-quinolinylcarbonyl)amino]ethyl]amino]ethyl]-,

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:744940 CAPLUS
DOCUMENT NUMBER: 130:25338
TITLE: Inhibitors of protein isoprenyl transferases
INVENTOR(S): Sebti, Said M.; Hamilton, Andrew D.; Augeri, David J.; Barr, Kenneth J.; Donner, Bernard G.; Fakhoury, Stephen A.; Janowick, David A.; Kalvin, Douglas M.; Larsen, John J.; Liu, Gang; O'Connor, Stephen J.; Rosenberg, Saul H.; Shen, Wang; Swenson, Rolf E.; Sorensen, Bryan K.; Sullivan, Gerard M.; Szczepankiewicz, Bruce G.; Tasker, Andrew S.; Wasick, James I.; Winn, Martin
PATENT ASSIGNEE(S): University of Pittsburgh, USA
SOURCE: PCT Int. Appl., 848 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9850029	A1	19981112	WO 1998-US9296	19980507
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2288330	A1	19981112	CA 1998-2288330	19980507
AU 9874733	A	19981127	AU 1998-74733	19980507
EP 986384	A1	20000322	EP 1998-922122	19980507
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002518985	T	20020625	JP 1998-548480	19980507
TW 492955	B	20020701	TW 1998-87107182	19980715
TW 541302	B	20030711	TW 1998-87107183	19980715
MX 9910186	A	20000630	MX 1999-10186	19991105
PRIORITY APPLN. INFO.:			US 1997-852858 A	19970507
			WO 1998-US9296 W	19980507

OTHER SOURCE(S): MARPAT 130:25338
AB Compds. R3-Z-L1-aryl [aryl is a benzene ring having certain substituents R1, R2, R4; L1 is absent or is L4NR5L5, L4OL5, L4S(O)mL5 (m = 0-2), etc., where L4 and L5 are absent or alkylene, alkenylene, R5 is H, alkanoyl; Z is a covalent bond, O, S(O)q (q = 0-2), NH or imino; R3 = H, aryl, fluorenyl, heterocyclyl, cycloalkyl, etc.] were prepared as inhibitors of protein isoprenyl transferases. Thus, N-[4-[(R)-thiazolidin-4-ylcarbonylamino]-2-phenylbenzoyl]methionine Me ester hydrochloride, prepared via amidation reaction, showed 92% inhibition of farnesyl transferase at 1x10-6 M.
IT 216231-94-6P 216234-40-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of inhibitors of protein isoprenyl transferases)
RN 216231-94-6 CAPLUS
CN L-Methionine, N-[[5-[(6-quinolinylamino)methyl][1,1'-biphenyl]-2-yl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 216234-40-1 CAPLUS
CN L-Methionine, N-[[5-[(butyl-2-quinolinylamino)methyl]-2'-methyl[1,1'-biphenyl]-2-yl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 216238-29-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of inhibitors of protein isoprenyl transferases)
RN 216238-29-8 CAPLUS
CN L-Methionine, N-[[5-[(butyl-2-quinolinylamino)methyl]-2'-methyl[1,1'-biphenyl]-2-yl]carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1980:471173 CAPLUS
DOCUMENT NUMBER: 93:71173
ORIGINAL REFERENCE NO.: 93:11561a,11564a
TITLE: Ligand structure and complexation. LI. Multidentate neutral ligands with variable cavities and pseudocavities
AUTHOR(S): Sieger, Heinz; Voegtle, Fritz
CORPORATE SOURCE: Inst. Org. Chem. Biochem., Univ. Bonn, Bonn, D-5300, Fed. Rep. Ger.
SOURCE: Liebigs Annalen der Chemie (1980), (3), 425-40
CODEN: LACHDL; ISSN: 0170-2041
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 93:71173
GI



AB New cyclic and acyclic netral ligands, e.g. I and II, contain repeating oligoethylene glycol ethers and carboxamide functions, which allow attractive interactions between single chain segments and with terminal groups. The complexation of Na+ and competing cations was studied by 23Na-NMR spectroscopy. Na+ was also displaced by neutral mols. such as urea. Chiral open-chain ligands and their complexation with alkali and alkaline earth metal salts were described.
IT 74129-21-8P 74136-81-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 74129-21-8 CAPLUS
CN Rubidium(1+),
[N,N',N''-tris[2-[2-[2-[2-(8-quinolinyloxy)ethoxy]ethoxy]ethoxy]phenyl]-1,3,5-benzenetricarboxamide]-, iodide (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



● I⁻

RN 74136-81-5 CAPLUS
CN Sodium(1+),
[N,N',N''-tris[2-[2-[2-[2-(8-quinolinyloxy)ethoxy]ethoxy]ethox

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
yl]phenyl]-1,3,5-benzenetricarboxamide]-, perchlorate (9CI) (CA INDEX NAME)

CM 1

CRN 74136-80-4
CMF C72 H72 N6 Na O15
CCI CCS

PAGE 1-A



L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 2-A



CM 2

CRN 14797-73-0
CMF Cl O4